Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing
Key Highlights
- ➤SkinJect LOI contemplates $135 million pre-money enterprise valuation
- ➤Concurrent equity financing would support SKNJCT-005 and potential NDA preparation
- ➤Medicus intends to retain majority economic and voting ownership
- ➤Proposed separately listed SkinJect company could close during first half of 2027
- ➤FDA issued “Study May Proceed” letter for planned Phase 2b study
Expert Statements
Dr. Raza Bokhari, Medicus Exec. Chairman and CEO
“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders”
Dr. Raza Bokhari, Medicus Exec. Chairman and CEO
“The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that, its wholly-owned subsidiary, Skinject, Inc. (“SkinJect”), has entered into a non-binding letter of intent ("LOI") with an undisclosed special purpose acquisition company ("SPAC") for a proposed business combination involving SkinJect (“Business Combination”). The LOI contemplates a $135 million pre-money enterprise valuation for SkinJect and concurrent equity financing to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential New Drug Application ("NDA").
The proposed transaction is intended to establish a separately listed company dedicated to SkinJect, with Medicus seeking to retain majority economic and voting ownership. This structure would provide a dedicated financing platform for SkinJect’s rare-disease dermatology program while preserving Medicus shareholders’ participation in its potential future value.
Get started
Create a free account to read the full story.